OraSure Technologies, Inc. (NASDAQ:OSUR) Holdings Raised by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. raised its stake in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 66.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 524,950 shares of the medical instruments supplier's stock after buying an additional 209,580 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.70% of OraSure Technologies worth $2,242,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Acadian Asset Management LLC lifted its holdings in OraSure Technologies by 38.1% in the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier's stock valued at $9,349,000 after purchasing an additional 605,324 shares in the last quarter. BNP Paribas Financial Markets increased its position in OraSure Technologies by 27.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier's stock worth $3,655,000 after purchasing an additional 183,191 shares in the last quarter. Deerfield Management Company L.P. Series C increased its position in shares of OraSure Technologies by 428.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 152,003 shares of the medical instruments supplier's stock worth $648,000 after acquiring an additional 123,248 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in OraSure Technologies by 74.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 163,542 shares of the medical instruments supplier's stock valued at $697,000 after purchasing an additional 69,625 shares in the last quarter. Finally, Millennium Management LLC raised its position in OraSure Technologies by 727.5% in the second quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier's stock valued at $8,610,000 after purchasing an additional 1,776,867 shares during the period. Institutional investors and hedge funds own 93.50% of the company's stock.

Analyst Ratings Changes

Separately, StockNews.com raised OraSure Technologies from a "hold" rating to a "buy" rating in a research report on Friday, October 4th.

OraSure Technologies Stock Performance

Shares of OSUR stock traded up $0.07 on Friday, hitting $3.91. The stock had a trading volume of 773,295 shares, compared to its average volume of 802,055. The stock's 50 day moving average is $4.04 and its 200-day moving average is $4.25. The firm has a market capitalization of $291.65 million, a price-to-earnings ratio of 26.07 and a beta of 0.03. OraSure Technologies, Inc. has a 52-week low of $3.72 and a 52-week high of $8.45.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The firm had revenue of $39.92 million during the quarter, compared to the consensus estimate of $38.97 million. During the same quarter in the prior year, the business posted $0.27 earnings per share. OraSure Technologies's revenue for the quarter was down 55.2% on a year-over-year basis. Equities analysts expect that OraSure Technologies, Inc. will post -0.07 earnings per share for the current year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.